Nanoparticles and methods of use
AssigneeCreighton University
InventorChristopher J. Destache
Life of this patent
Estimating the term…
Abstract
Provided herein are nanoparticles and methods for using nanoparticles. The nanoparticles include at least three antiretroviral agents. When introduced to cells the nanoparticles cause an increase in the intracellular concentration of the antiretroviral agents to a level that is at least the IC50 against HIV-I or HIV-2. This concentration may be maintained for at least 21 days after the cells are contacted with the nanoparticle. When administered to a subject the nanoparticles cause the concentration of the antiretroviral agents to increase to at least 100 ng/ml in the serum of the subject, at least 0.5 μg/gram tissue in an organ of the subject, or a combination thereof. Such a concentration may be maintained for at least 21 days after the administration.
Claims24
A method for delivering a particle to phagocytic cells, the method comprising:
- contacting a phagocytic cell with an effective amount of a composition comprising the particles under conditions suitable for uptake of the particles by the phagocytic cell, wherein the particles comprise at least three antiretroviral agents, and wherein the particles have an average size of from 10 nanometers to 750 nanometers.
-4. (canceled)
-21. (canceled)
-27. (canceled)
-46. (canceled)
A method for increasing the concentration of an agent in a subject, the method comprising:
- administering to a subject an effective amount of a composition comprising particles, wherein the particles comprise at least three antiretroviral agents, wherein the particles have an average size of from 10 nanometers to 750 nanometers, wherein a single administration results in a concentration of at least one antiretroviral agent of at least 100 ng/ml in the serum of the subject, at least 0.5 μg/gram tissue in an organ of the subject, or a combination thereof, for at least 21 days after the administration.
A particle comprising at least three antiretroviral agents, wherein the particles have an average size of from 10 nanometers to 750 nanometers, wherein the particle has a surface charge of between −40 mV and −2 mV, and wherein the particle comprises PLGA.
Dependencies are inferred from the claim text.